Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Lincoff

Showing results (101-110 of 116) with videos related to

Pageof 12
Sort By:
Circulation|June 7, 2000
Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT InvestigatorsE Boersma, K S Pieper, E W Steyerberg, et al.
Journal of the American College of Cardiology|February 24, 2001
Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT InvestigatorsA B Greenbaum, R A Harrington, M P Hudson, et al.
Circulation|June 9, 1999
Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experienceM W McClure, S D Berkowitz, R Sparapani, et al.
Circulation|August 22, 2001
Abciximab readministration: results of the ReoPro Readministration RegistryJ E Tcheng, D J Kereiakes, A M Lincoff, et al.
Circulation|May 11, 1999
Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT InvestigatorsK W Mahaffey, R A Harrington, M L Simoons, et al.
Alimentary Pharmacology & Therapeutics|April 19, 2018
Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trialN D Yeomans, D Y Graham, M E Husni, et al.
Circulation|September 7, 2000
Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trialA M Lincoff, R A Harrington, R M Califf, et al.
Lancet (London, England)|April 12, 2001
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational studyH D Aronow, E J Topol, M T Roe, et al.
Journal of Thrombosis and Haemostasis : JTH|March 8, 2005
First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS TrialJ H Alexander, H Yang, R C Becker, et al.
The American Journal of Cardiology|February 1, 1997
Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG InvestigatorsA M Lincoff, J E Tcheng, R M Califf, et al.
Pageof 12

Showing results (101-110 of 116) with videos related to

Sort By:
Pageof 12
Circulation|June 7, 2000
Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT InvestigatorsE Boersma, K S Pieper, E W Steyerberg, et al.
Journal of the American College of Cardiology|February 24, 2001
Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT InvestigatorsA B Greenbaum, R A Harrington, M P Hudson, et al.
Circulation|June 9, 1999
Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experienceM W McClure, S D Berkowitz, R Sparapani, et al.
Circulation|August 22, 2001
Abciximab readministration: results of the ReoPro Readministration RegistryJ E Tcheng, D J Kereiakes, A M Lincoff, et al.
Circulation|May 11, 1999
Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT InvestigatorsK W Mahaffey, R A Harrington, M L Simoons, et al.
Alimentary Pharmacology & Therapeutics|April 19, 2018
Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trialN D Yeomans, D Y Graham, M E Husni, et al.
Circulation|September 7, 2000
Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trialA M Lincoff, R A Harrington, R M Califf, et al.
Lancet (London, England)|April 12, 2001
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational studyH D Aronow, E J Topol, M T Roe, et al.
Journal of Thrombosis and Haemostasis : JTH|March 8, 2005
First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS TrialJ H Alexander, H Yang, R C Becker, et al.
The American Journal of Cardiology|February 1, 1997
Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG InvestigatorsA M Lincoff, J E Tcheng, R M Califf, et al.
Pageof 12